Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Conditions

Hyperphagia 3Short Bowel Syndrome 2Pena Shokeir syndrome, type 1 2

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × soybean oil, phospholipid emulsion × Clear all
NCT04555044 2023-12-27

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

Baxter Healthcare Corporation

Phase 4 Completed
101 enrolled 29 charts

Pena Shokeir syndrome, type 1, Hyperphagia, Short Bowel Syndrome

NCT02476994 2021-07-21

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Baxter Healthcare Corporation

Phase 4 Terminated
1 enrolled 4 charts

Pena Shokeir syndrome, type 1, Hyperphagia, Short Bowel Syndrome

NCT00292279 2008-05-14

The Impact of Omega-3 Fat Emulsion on Clinical Outcome of Post-Operative Cancer Patients

Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd

Phase 3 Completed
206 enrolled

Hyperphagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡